Physician profile
Diane Holmes
NPI 1518341965
$1,247.99
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $610 · 2024: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $98.63 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.41 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $92.84 | 2022-2024 | Rexulti |
| Abbvie INC. | $84.46 | 2022-2024 | |
| Medtronic, INC. | $80.63 | 2022 | |
| Lundbeck LLC | $78.27 | 2022-2024 | Rexulti |
| Amgen INC. | $78.17 | 2021-2024 | Krystexxa |
| Abbott Laboratories | $68.64 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $58.55 | 2022-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $56.46 | 2024 | |
| Alkermes, INC. | $52.49 | 2022-2024 | Vivitrol |
| Orexo US, INC. | $47.98 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $42.46 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $36.30 | 2021-2022 | |
| Indivior INC. | $28.86 | 2024 | Sublocade |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $28.15 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.13 | 2022 | |
| Novo Nordisk INC | $24.16 | 2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $23.41 | 2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $22.99 | 2024 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $22.52 | 2022 | |
| Lilly USA, LLC | $18.54 | 2024 | Jardiance |
| Pfizer INC. | $18.40 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.91 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $16.38 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Jazz Pharmaceuticals INC. | $15.06 | 2024 | |
| Grt US Holding, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.